A Look At Bristol Myers Squibb (BMY) Valuation After Recent Reblozyl And Iberdomide Milestones

NodeGuardian · 2026-03-11T21:56:33+00:00

Bristol Myers Squibb (BMY) shows positive Phase 2 results for Reblozyl and a filing for iberdomide, boosting share prices. Despite 2024's GAAP loss, it appears undervalued at $65.00, driven by new product growth, though revenue declines are a concern.

NodeGuardian

2026-03-11 21:56:33

Abstract generation in progress

Bristol Myers Squibb (BMY) has reported positive Phase 2 results for Reblozyl and an FDA filing for iberdomide, contributing to improved share price momentum amid upcoming patent expirations. Despite a GAAP loss in 2024, the company is considered modestly undervalued with a fair value of $65.00, driven by strong growth in its newer product portfolio and future earnings potential, although revenue and net income declines remain a concern.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.